Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShire Regulatory News (SHP)

  • There is currently no data for SHP

Form 8.5 (EPT/NON-RI) - SHIRE PLC

24 Dec 2018 11:20

RNS Number : 4458L
Morgan Stanley
24 December 2018
Β 

Β 

Β FORM 8.5 (EPT/NON-RI)

Β 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY ("RI") STATUS (OR WHERE RI STATUS IS NOT APPLICABLE)

Rule 8.5 of the Takeover Code (the "Code")

Β 

1. KEY INFORMATION

Β 

(a) Name of exempt principal trader:

Morgan Stanley Capital Products LLC

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Shire plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Shire plc

(d) Date position held/dealing undertaken

For an opening position disclosure, state the latest practicable date prior to the disclosure

21 DECEMBER 2018

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

Yes - Takeda Pharmaceutical Company Limited

Β 

Β 

Β 

2. POSITIONS OF THE EXEMPT PRINCIPAL TRADER

Β 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

Β 

Β (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Β 

Β Class of relevant security:

5p ordinary

Β 

Β Interests

Short positions

Β 

Β Number

%

Number

%

Β (1) Relevant securities owned Β and/or controlled:

0

Β 0.00

Β 0

0.00

Β 

Β (2) Cash-settled derivatives:

0

Β 0.00

Β 490

0.00

Β 

Β (3) Stock-settled derivatives (including options) and agreements to purchase/sell:

0

Β 0.00

Β 0

0.00

Β 

TOTAL:

0

Β 0.00

Β 490

0.00

Β 

Β 

Β 

All interests and all short positions should be disclosed.

Β 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

Β 

(b) Rights to subscribe for new securities (including directors' and other employee options)

Β 

Β Class of relevant security in relation to which subscription right exists:

Β N/A

Β Details, including nature of the rights concerned and relevant percentages:

Β N/A

Β 

Β 

3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER

Β 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

Β 

The currency of all prices and other monetary amounts should be stated.

Β 

Β 

(a) Purchases and sales

Β 

Β Class of

relevant

security

Β Purchases/

sales

Β Total number

of securities

Β Highest price

per unit paid/received

Β Lowest price

per unit paid/received

Β N/A

Β N/A

Β N/A

Β N/A

Β N/A Β 

Β 

Β 

(b) Cash-settled derivative transactions

Β 

Class of

relevant

security

Β Product description

Β e.g. CFD

Β Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Β Number of reference securities

Β Price per

unit

Β 5p ordinary

Β CFD

Β LONG

Β 69

Β 44.8950 GBP

Β 

Β 5p ordinary

Β CFD

Β LONG

Β 9

Β 44.8950 GBP

Β 

Β 5p ordinary

Β CFD

Β LONG

Β 14

Β 44.8950 GBP

Β 

Β 5p ordinary

Β CFD

Β LONG

Β 2

Β 44.8950 GBP

Β 

Β 

(c) Stock-settled derivative transactions (including options)

Β 

(i) Writing, selling, purchasing or varying

Β 

Β Class

of

relevant

security

Β Product description Β e.g. call option

Β Writing, purchasing,

selling,

varying etc.

Β Number

of securities to which option relates

Β Exercise price

per unit

Β Type

e.g. American, European etc.

Β Expiry date

Β Option money paid/ received per unit

Β 

Β N/A

Β N/A

Β N/A

Β N/A

Β N/A

Β N/A

Β N/A

Β N/A Β 

Β 

Β 

(ii) Exercise

Β 

Β Class of

relevant

security

Β Product description

e.g. call option

Β Exercising/

exercised

against

Β Number of securities

Β Exercise price

per unit

Β 

Β N/A

Β N/A

Β N/A

Β N/A

Β N/A Β 

Β 

Β 

(d) Other dealings (including subscribing for new securities)

Β 

Β Class of relevant

security

Β Nature of dealing

e.g. subscription, conversion

Β Details

Β Price per unit (if applicable)

Β N/A

Β N/A

Β N/A

Β N/A Β 

Β 

Β 

Β 

4. OTHER INFORMATION

Β 

(a) Indemnity and other dealing arrangements

Β 

Details of any indemnity or option arrangement, or any agreement or understanding,

formal or informal, relating to relevant securities which may be an inducement to deal

or refrain from dealing entered into by the exempt principal trader making the

disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

Β 

NONE

Β 

Β 

Β 

Β (b) Agreements, arrangements or understandings relating to options or derivatives

Β 

Details of any agreement, arrangement or understanding, formal or informal, between

the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

Β 

NONE

Β 

Β 

(c) Attachments

Β 

Is a Supplemental Form 8 (Open Positions) attached?

NO Β 

Β 

Β 

Β 

Β Date of disclosure:

Β 24 DECEMBER 2018

Β 

Β Contact name:

Β Craig Horsley

Β 

Β Telephone number:

Β +44(141) 245 7736

Β 

Β 

Β 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

Β 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

Β 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

Β 

Β 

Β 

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Β 
END
Β 
Β 
FEOMMMZZMDVGRZM
Date   Source Headline
8th Jan 20195:30 pmGNWDirector/PDMR Shareholding
8th Jan 20193:20 pmRNSForm 8.3 - Shire plc
8th Jan 20193:19 pmRNSForm 8.3 - Takeda Pharmaceutical Company Limited
8th Jan 20193:13 pmRNSForm 8.3 - Shire plc
8th Jan 20193:07 pmRNSForm 8.5 (EPT/NON-RI)
8th Jan 20192:28 pmRNSForm 8.5 (EPT/RI) - Replacement of Shire
8th Jan 20192:23 pmRNSForm 8.5 (EPT/RI) - Replacement of Shire
8th Jan 20192:21 pmRNSForm 8.5 (EPT/RI) - Replacement of Shire
8th Jan 20191:57 pmRNSForm 8.3 - Takeda Pharmaceutical Company Limited
8th Jan 20191:27 pmRNSForm 8.3 - Shire plc
8th Jan 201912:31 pmRNSForm 8.3 - Takeda Pharmaceutical Company Limited
8th Jan 201912:29 pmRNSForm 8.3 - Takeda Pharmaceutical
8th Jan 201912:27 pmRNSForm 8.3 - Shire plc
8th Jan 201911:42 amRNSForm 8.5 (EPT/NON-RI)
8th Jan 201911:33 amRNSForm 8.5 (EPT/NON-RI)- Shire Plc
8th Jan 201910:49 amRNSForm 8.5 (EPT/RI)
8th Jan 201910:41 amRNSForm 8.3 - Takeda Pharmaceutical Company Limited
8th Jan 201910:26 amRNSForm 8.5 (EPT/RI)- Shire plc
8th Jan 20199:51 amRNSForm 8.3 - Shire Plc
8th Jan 20198:44 amRNSForm 8.5 (EPT/RI) - SHIRE PLC
8th Jan 20197:00 amRNSForm 8.3 - Takeda Pharmaceutical Company Limited
8th Jan 20197:00 amGNWScheme becomes effective
7th Jan 20195:00 pmGNWHolding(s) in Company
7th Jan 20193:42 pmRNSForm 8.5 (EPT/RI) - Amendment
7th Jan 20193:20 pmRNSForm 8.3 - Shire plc
7th Jan 20193:02 pmRNSForm 8.3 - Shire plc
7th Jan 20193:00 pmRNSForm 8.5 (EPT/NON-RI)
7th Jan 20193:00 pmRNSForm 8.3 - Shire plc
7th Jan 20192:59 pmRNSForm 8.3 - Takeda Pharmaceutical
7th Jan 20192:50 pmPRNForm 8.3 - Shire Plc
7th Jan 20192:49 pmRNSForm 8.3 - Shire plc
7th Jan 20192:47 pmRNSForm 8.3 - Takeda Pharmaceutical Company Limited
7th Jan 20192:45 pmBUSForm 8.3 - Shire plc
7th Jan 20191:55 pmRNSForm 8.3 - Takeda Pharmaceutical Company Limited
7th Jan 20191:54 pmRNSForm 8.3 - Shire plc
7th Jan 20191:39 pmRNSForm 8.3 - [Shire Plc]
7th Jan 20191:32 pmRNSForm 8.5 (EPT/RI) - Replacement of Shire
7th Jan 20191:29 pmRNSForm 8.5 (EPT/RI) - Replacement of Shire
7th Jan 201912:57 pmRNSForm 8.3 - Takeda Pharmaceutical Company Limited
7th Jan 201912:56 pmRNSForm 8.3 - Shire plc
7th Jan 201912:42 pmRNSForm 8.5 (EPT/NON-RI)
7th Jan 201911:52 amRNSForm 8.3 - Takeda Pharmaceutical Company Limited
7th Jan 201911:43 amBUSForm 8.3 - SHIRE PLC
7th Jan 201911:30 amRNSForm 8.3 - Takeda Pharmaceutical Company Limited
7th Jan 201911:27 amRNSForm 8.3 - Shire plc
7th Jan 201911:01 amRNSForm 8.5 (EPT/RI)- Shire plc
7th Jan 201910:59 amRNSForm 8.5 (EPT/NON-RI)- Shire Plc
7th Jan 201910:35 amRNSForm 8.5 - Shire plc
7th Jan 201910:16 amRNSForm 8.5 (EPT/RI) - SHIRE PLC
7th Jan 201910:13 amRNSForm 8.5 (EPT/RI) - Amendment

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.